home page about us location menu contacts menu
NeoCardium Limited is a company incorporated in United Kingdom with a focus in developing and assisting development of a new category of cardiology devices. The clinical indications for company’s proprietary device technology include applications in the practice of interventional cardiology and the new branch of Regenerative Cardiology...read more

  
ORIP OneTouch:

ORIP OneTouch is not just another medical device; it is a platform technology that has wide range of potential applications based on proven effects of remote ischemic pre-conditioning...                      read more

 
  CONSULTING
Our business is helping companies succeed in mending broken hearts. Regenerative Cardiology is all that we do for our clients, and do it as no one else does.      read more
 

ORIP OneTouch

ORIP OneTouch is not just another medical device; it is a platform technology that has wide range of potential applications based on proven effects of remote ischemic pre-conditioning in ischemia-reperfusion injuries reported in peer reviewed literature (See References below). Such injuries are very common in practice of Emergency Medicine, Critical Care, Surgery and Interventional Cardiology. Currently following device versions of the patent pending ORIP technology are under development, each of which target a multi-hundred million dollar market segment with very high unmet need:

ORIP OneTouch EMS: An Emergency Medical Service delivered while the patient is transported in an ambulance or in an emergency room and designed to protect against any ischemia-reperfusion injuries that could be caused druing emergency procedures that may be performed on the patient to save his/her life.

ORIP OneTouch CC: In critical care for treatment of critically ill patients for reducing the risk of developing Multiple Organ Dysfunction Syndrome.

ORIP OneTouch P3: Pre-Procedure Preparation for elective surgeries such as heart bypass or angioplasty for reducing ischemia-reperfusion injuries.

ORIP OneTouch CMS: A Chronic Medical Service device in long term management of patients for reducing risk of cardiovascular events.

ORIP OneTouch Neo: As an adjunct to the protein, gene or stem cell therapy for boosting neocardiogenesis in heart repair treatment.

ORIP OneTouch Angio: As an adjunct for post-angioplasty restenosis prevention.

Select References:
1. Ali Z A etl. Remote ischemic preconditioning reduces myocardial and renal injury after elective abdominal aortic aneurysm repair: a randomized controlled trial. Circulation. 2007 Sep 11;116(11 Suppl):I98-105.
2. Venugopal V et al. ''Conditioning'' the heart during surgery Eur. J. Cardiothorac. Surg. 2009;35:977-987. 3. Ovize M & Bonnefoy E. Giving ischaemic heart a short in the arm. The Lancet, 2010; Vol 375:9716, 699 -700, 27.
4. Botker H E, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patient with acute myocardial infarction. The Lancet, 2010; Vol 375:9716, 727 - 734, 27.

Home | Services | Product Development | ORIP OneTouch | Partners | News | Contact Us
Copyright © NeoCardium. Designed by MriLimited - mrilimited.com